Corporation, a biopharmaceutical company specializing in proprietary therapeutics with a market capitalization of $14 billion ...

Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most ...

Collaboration to take Cytovation’s synthetic peptide, CY-101, into a Phase 2 trial for patients with adrenocortical carcinomaCancer Research UK’s ...

The short answer is yes, PCOS has a complex genetic predisposition. However, lifestyle and environmental factors also play a ...

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis®) with ...

A new resource from the National Comprehensive Cancer Network (NCCN) provides evidence-based guidance on assessing and ...

The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.

Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the ...

The Harvard Center for International Development (CID) is a research center working across the University and a global network of researchers and practitioners to build an international pool of talent ...